COVend

The aim of the COVend project is to deliver an effective therapy against endothelial damage in ARDS for the clinical management of COVID-19 and other diseases.

[COVend @COVend_EU]

🎙️ Join us for a conversation with Prof Guenther Eissner and his dedicated team of researchers at @sysbioire @ucddublin, as they discuss their groundbreaking research on the potential of the drug FX06 in the COVend project.
🔗https://t.co/ZW0jSxRdZa

[COVend @COVend_EU]

🌟 FAQ #7: Are any of the tests used in the #IXION 2.0 study painful or dangerous?
💊 The safety of FX06 has been demonstrated in Phase 1 and Phase 2 studies. In case of any adverse reactions, the medical team will stop the medication and closely monitor the participant's health.

[COVend @COVend_EU]

🎉Congrats to Zhiran Wang and Günther Eißner, our #COVend partners from @ucddublin, @sysbioire, on their participation in the 7th European Congress of Immunology in Dublin!
👇 Read the article and learn more about their breakthrough research results 🔬
https://t.co/JgbQNom16W

[COVend @COVend_EU]

🩺Proudly joining the global community in acknowledging #worldpatientsafetyday as we at #COVend prioritise the safety and well-being of patients. Our mission is the need to address #ARDS, a life-threatening condition that has a devastating impact on patients and their families.

[COVend @COVend_EU]

💡 COVend was featured in #Horizon magazine for our innovative and nature-inspired approach to treating acute respiratory distress syndrome #ARDS. Read the article "Breathing easier – nature-inspired treatments could relieve acute respiratory distress".
🔗https://t.co/OowEFxIOPl

[COVend @COVend_EU]

🎯COVend partner, Zhiran Wang from @ucddublin, will present her poster "The Protective Effects of the Fibrin-derived Peptide FX06 on Human Pulmonary Endothelial Cells Against COVID-19-Triggered Cytokines" at booth P1.14.24 on 02.09 at 7th European Congress of Immunology in Dublin

[COVend @COVend_EU]

🌟FAQ #6: How long is the IXION 2.0 study?
Our study duration for individual patients will be maximally 28 days (plus up to 2-day screening period) for the main study period, with a follow-up telephone call at day 60.📅
Learn more👉https://t.co/aTn5sHu6fO
#COVend #ARDS #HorizonEU

[COVend @COVend_EU]

🚀 COVend is addressing #EU policy priorities and global challenges through R&I.💊 Our therapeutic candidate, #FX06, could be a game-changer in fighting #ARDS.💪🌍 Stay informed about our efforts to improve healthcare in the EU.
👉 https://t.co/G6U4HFuSyT

[COVend @COVend_EU]

#Endothelialprotection during #acuterespiratorydistress syndrome (#ARDS) is the focus of IXION2.0, the #clinicaltrial within the #COVend project, & our research will provide important insights into understanding and combating #IRI. Read the full post👉https://t.co/BQEbpNWldP

[COVend @COVend_EU]

📢#COVend Presented at #Euroanaesthesia2024 Congress in Munich! For a detailed account of COVend’s participation read the full post
👉https://t.co/1WunK0X79y 📰Thank you to our #projectpartners from @ESAIC_org for a fantastic congress!! 🙌 #EA24 #biotech #IXION #ARDS #EUfunded

[COVend @COVend_EU]

🌟 FAQ #3: What is FX06? #FX06 is a naturally occuring #peptide that stabilises the blood vessels in the lungs. Learn more about FX06 as a potential therapy for the management of #ARDS 👉 https://t.co/z3JS16IlJ8 #COVend #ClinicalTrial #HorizonEurope

[COVend @COVend_EU]

🌟 #FAQ 2: What is the #IXION 2.0 Study about?
The study aims to contribute to advancing medical knowledge and potentially improving outcomes for those facing #ARDS using #FX06. Learn how 👉https://t.co/G6U4HFvqor #EUproject #IXIONClinicalTrial #ARDSResearch #MedicalAdvancements

[COVend @COVend_EU]

📢 Exciting news! We are pleased to announce that the COVend will be showcased at #Euroanaesthesia2024, #EA24 in Munich, an event hosted by our partners from @ESAIC_org.
Join us on Monday, May 27 at 09:15 am at the ESAIC Expo to learn more about COVend!
https://t.co/gcoIRUNQ8K

[COVend @COVend_EU]

Congrats to our COVend partners from SBI @ucddublin & Zhiran Wang on the successful presentation of their groundbreaking research on the Fibrin-derived Peptide FX06 Protecting Human Pulmonary Endothelial Cells Against COVID-19-Triggered Cytokines at the
@embl @EMBO Workshop 2024

[COVend @COVend_EU]

Attending @EMBLBarcelona this week?

Visit Zhiran Wang’s Poster Presentation at EMBO Workshop 2024! 👀 Don’t Miss It! Visit booth 112 during the poster session tomorrow May 7th, from 18:00 to 20:00! #EMBLBarcelona #VascularBiology #COVID19Research #EMBO

[ESAIC @ESAIC_org]

🌐Come and meet us at #EA24 during ESAIC Expo sessions:

25 MAY: Challenges ahead – Sustainability and Scientific Publications
26 MAY: Broadening skills and horizons
27 MAY: Promoting research and safety

🔗https://t.co/N46B0VKkNL

[COVend @COVend_EU]

Attending the @EMBO workshop at @EMBLEvents Barcelona this week? Be sure to check out #COVend researcher Zhiran Wang's poster presentaiton on "The Fibrin-derived Peptide #FX06 Protects Human Pulmonary #Endothelial Cells Against #COVID19 Triggered #Cytokines” - details below👇

[COVend @COVend_EU]

📢Exciting news! The #COVend project’s IXION 2.0 Clinical study is currently underway! Over the coming weeks, we will be sharing #FAQs to address common inquiries about the #IXION 2.0 clinical study. Learn about #ClinicalTrials in general here
👉 https://t.co/NcsMCDouod

[COVend @COVend_EU]

📢 Press Release: The #COVend press release announces the start of patient enrollment for the IXION 2.0 clinical study and project’s shift to investigating the potential benefits of the FX06 drug for patients with #ARDS ! Read the full details here📷https://t.co/JuRTAl7Q71

[COVend @COVend_EU]

We’re thrilled to welcome two new patients to the #IXION2.0 clinical trial. This marks a big step forward in #COVend ’s unwavering commitment to finding immediately available, precisely defined, and cost-effective treatment for #ARDS. Read more here https://t.co/JuRTAl7Q71